CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women

Conditions

Ovarian Cancer

Keywords

ovarian epithelial cancer

Brief summary

RATIONALE: Screening tests may help doctors detect ovarian cancer early when the survival is much more encouraging. It is not yet known whether a CA125-based or ultrasound strategy is more effective in detecting ovarian cancer early thereby impacting on the mortality from the disease in postmenopausal women from the general population. PURPOSE: Randomized clinical trial to assess the impact of screening using a multimodal strategy using CA125 interpreted by the Risk of Ovarian Cancer Algorithm (ROCA) followed by transvaginal ultrasound as a second line test versus transvaginal ultrasound on mortality from the disease in postmenopausal women from the general population.

Detailed description

OBJECTIVES: * Determine the impact of preclinical detection of ovarian cancer by screening on ovarian cancer mortality in postmenopausal women. * Determine the physical morbidity of ovarian cancer screening in this population. * Determine the psychological consequences of screening results (true negative, true positive, false negative, and false positive) in this population. * Compare the interventions that result from screening for ovarian cancer using CA 125 monitoring and ultrasound in this population. * Compare the feasibility of population screening, in terms of compliance rates with annual screening for ovarian cancer with these strategies. * Compare the performance of these screening strategies in this population. OUTLINE: This is a randomized, multicenter study. Participants are randomized to 1 of 3 screening arms. * Arm I: Participants do not undergo screening. * Arm II: Participants undergo screening with an annual CA 125 level interpreted using the Risk of Ovarian Cancer Algorithm (ROCA). Depending on the results of the test, some patients may undergo additional screening. * Arm III: Participants undergo screening with an annual transvaginal or transabdominal ultrasound. Depending on the results of the test, some patients may undergo additional screening. Participants in all arms complete a health questionnaire at 3-5 years after study entry and in 2014. PROJECTED ACCRUAL: A total of 200,000 participants (100,000 for arm I and 50,000 each for arms II and III) will be accrued for this study within 5 years.

Usha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, Andy Ryan, Jatinderpal K Kalsi et al. (13 authors)

Health Technology Assessment2025-03-01

10.3310/nhym3608

Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

Usha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, Andy Ryan, Jatinderpal K Kalsi et al. (13 authors)

Health Technology Assessment2025-03-01

10.3310/ckuy6010

Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Dilley J, Gentry-Maharaj A, Ryan A, Burnell M, Manchanda R, Kalsi J, Singh N, Woolas R, Sharma A, Williamson K, Mould T, Fallowfield L, Campbell S, Skates SJ, McGuire A, Parmar M, Jacobs I, Menon U.

2023-11-185 citations

10.1016/j.ygyno.2023.11.005

Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial.

Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Singh N, Manchanda R, Kalsi JK, Woolas R, Arora R, Casey L, Dawnay A, Sharma A, Williamson K, Apostolidou S, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs IJ, Parmar MKB.

2023-09-0134 citations

10.1016/s1470-2045(23)00335-2

Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials

Usha Menon, Aleksandra Gentry‐Maharaj, Matthew Burnell, Sophia Apostolidou, Andy Ryan et al. (14 authors)

Health Technology Assessment2023-08-015 citations

10.3310/cldc7214

Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, Kalsi JK, Woolas R, Manchanda R, Arora R, Casey L, Dawnay A, Dobbs S, Leeson S, Mould T, Seif MW, Sharma A, Williamson K, Liu Y, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs IJ, Parmar M.

2021-05-12472 citations

10.1016/s0140-6736(21)00731-5

Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

Jatinderpal Kalsi, Aleksandra Gentry‐Maharaj, Andy Ryan, Naveena Singh, Matthew Burnell et al. (21 authors)

Cancers2021-02-188 citations

10.3390/cancers13040858

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ.

2015-12-17702 citations

10.1016/s0140-6736(15)01224-6

Identifying hopelessness in population research: a validation study of two brief measures of hopelessness

Lindsay Fraser, Matthew Burnell, Laura Currin, Evangelia‐Ourania Fourkala, Jatinderpal Kalsi et al. (10 authors)

BMJ Open2014-05-0154 citations

10.1136/bmjopen-2014-005093

Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.

Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, Ryan A, Seif MW, Amso NN, Turner G, Brunell C, Fletcher G, Rangar R, Ford K, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Skates SJ, Fallowfield L, Fallowfield L, Parmar M, Campbell S, Menon U.

2010-12-10122 citations

10.1016/s1470-2045(10)70268-0

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I.

2009-03-11517 citations

10.1016/s1470-2045(09)70026-9

Interventions

OTHERscreening questionnaire administration

PROCEDUREannual screening

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Intervention model description

202,638 participants randomised to: Multimodal Group: 50640 Ultrasound Group: 50639 Control Group: 101359

Eligibility

Sex/Gender

FEMALE

Age

50 Years to 74 Years

Healthy volunteers

Yes

Inclusion criteria

DISEASE CHARACTERISTICS: * Postmenopausal, as defined by meeting 1 of the following criteria: * More than 12 months of amenorrhea after natural menopause or hysterectomy * Received more than 12 months of hormone replacement therapy for menopausal symptoms * No prior ovarian malignancy * No prior bilateral oophorectomy * Not at high risk for ovarian cancer due to familial predisposition as defined by the UKCCCR Familial Ovarian Cancer Screening Study PATIENT CHARACTERISTICS: Age * 50 to 74 Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified Other * No active non-ovarian malignancy * Prior malignancy allowed provided there is no documented persistent or recurrent disease and patient has not received treatment for more than 1 year PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * See Disease Characteristics Radiotherapy * Not specified Surgery * See Disease Characteristics Other * No concurrent participation in any other ovarian cancer screening study

Design outcomes

Primary

Measure	Time frame
UKCTOCS (2001-2014): Death due to ovarian cancer (WHO 2003) determined by independent outcomes committee review of patient notes for all women identified to have a 'possible ovarian cancer' (pre-specified ICD-10 codes) till 31st December 2014.	—
Long term impact of screening on ovarian cancer mortality in the UKCTOCS (LTFU UKCTOCS) (2015-2021): Death due to ovarian cancer (WHO 2014) determined by independent outcomes committee review till 30 June 2020.	—

Secondary

Measure	Time frame	Description
Cost-effectivenesss of the multimodal (MMS) and ultrasound screening (USS) strategies separately comparing them to a no-screening arm.	—	Cost-effectivenesss of the multimodal (MMS) and ultrasound screening (USS) strategies separately comparing them to a no-screening arm: (a) Incremental cost-effectiveness analysis over the 14 year period of the trial (censorship 31st Dec 2014); (b) Incremental cost-effectiveness analysis for the cumulative mortality estimated over a 25-year period by extrapolating beyond the 14 years of the trial
Performance characteristics: Sensitivity, specificity, positive predictive values of the two screening strategies (multimodal and ultrasound) for detection of ovarian cancer diagnosed within one year of last screen.	—	Ovarian cancer diagnosis is based on outcomes review of medical notes of all women who developed ovarian cancer during the trial.
Psychological morbidity related to screening - assessed in a separate MRC funded study, UKCTOCS Psychosocial study, PI Prof Dame Lesley Fallowfield.	—	—
Compliance with annual screening: The proportion of women who attended all tests that formed part of an annual screening episode of the total who were eligible for that annual screening episode.	—	—
Surgical complications in women who underwent false positive surgery and were found to have benign or normal adnexae.	—	This is assessed through central medical note review and assigned by designated trial gynaecological oncologist.

Outcome results

None listed